These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 7730497)

  • 21. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
    Kapur S; Remington G
    Annu Rev Med; 2001; 52():503-17. PubMed ID: 11160792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopamine D2 and D4 receptor ligands: relation to antipsychotic action.
    Wilson JM; Sanyal S; Van Tol HH
    Eur J Pharmacol; 1998 Jun; 351(3):273-86. PubMed ID: 9721018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens.
    Ichikawa J; Kuroki T; Dai J; Meltzer HY
    Eur J Pharmacol; 1998 Jun; 351(2):163-71. PubMed ID: 9686999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus.
    Li Z; Huang M; Prus AJ; Dai J; Meltzer HY
    Brain Res; 2007 Feb; 1134(1):70-8. PubMed ID: 17207474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
    Schotte A; Janssen PF; Gommeren W; Luyten WH; Van Gompel P; Lesage AS; De Loore K; Leysen JE
    Psychopharmacology (Berl); 1996 Mar; 124(1-2):57-73. PubMed ID: 8935801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risperidone inhibits 5-hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5-hydroxytryptamine.
    Hertel P; Nomikos GG; Svensson TH
    Br J Pharmacol; 1997 Dec; 122(8):1639-46. PubMed ID: 9422809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atypical neuroleptic drugs downregulate dopamine sensitivity in rat cortical and striatal astrocytes.
    Reuss B; Unsicker K
    Mol Cell Neurosci; 2001 Aug; 18(2):197-209. PubMed ID: 11520180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The affinity of antipsychotic drugs to dopamine and serotonin 5-HT
    Tollens F; Gass N; Becker R; Schwarz AJ; Risterucci C; Künnecke B; Lebhardt P; Reinwald J; Sack M; Weber-Fahr W; Meyer-Lindenberg A; Sartorius A
    Eur Neuropsychopharmacol; 2018 Sep; 28(9):1035-1046. PubMed ID: 30006253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Receptor mechanisms in the treatment of schizophrenia.
    Reynolds GP
    J Psychopharmacol; 2004 Sep; 18(3):340-5. PubMed ID: 15358977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes.
    Moran-Gates T; Massari C; Graulich A; Liégeois JF; Tarazi FI
    J Neurosci Res; 2006 Aug; 84(3):675-82. PubMed ID: 16810690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences.
    Aringhieri S; Carli M; Kolachalam S; Verdesca V; Cini E; Rossi M; McCormick PJ; Corsini GU; Maggio R; Scarselli M
    Pharmacol Ther; 2018 Dec; 192():20-41. PubMed ID: 29953902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone.
    Ohno Y; Ishida-Tokuda K; Ishibashi T; Sakamoto H; Tagashira R; Horisawa T; Yabuuti K; Matsumoto K; Kawabe A; Nakamura M
    Pol J Pharmacol; 1997 Aug; 49(4):213-9. PubMed ID: 9437764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New insights into the biology of schizophrenia through the mechanism of action of clozapine.
    Brunello N; Masotto C; Steardo L; Markstein R; Racagni G
    Neuropsychopharmacology; 1995 Nov; 13(3):177-213. PubMed ID: 8602893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serotonin and dopamine interactions in psychosis prevention.
    Richtand NM; McNamara RK
    Prog Brain Res; 2008; 172():141-53. PubMed ID: 18772031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimanic potency of typical neuroleptic drugs and affinity for dopamine D2 and serotonin 5-HT2A receptors--a new analysis of data from the archives and implications for improved antimanic treatments.
    Harrison-Read PE
    J Psychopharmacol; 2009 Nov; 23(8):899-907. PubMed ID: 18635692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New antipsychotics: classification, efficacy, and adverse effects.
    Gerlach J
    Schizophr Bull; 1991; 17(2):289-309. PubMed ID: 1715608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
    Leysen JE; Janssen PM; Megens AA; Schotte A
    J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia.
    Meltzer HY; Massey BW; Horiguchi M
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1572-86. PubMed ID: 22283753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The mechanism of action of novel antipsychotic drugs.
    Meltzer HY
    Schizophr Bull; 1991; 17(2):263-87. PubMed ID: 1679253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.
    Depoortère R; Bardin L; Auclair AL; Kleven MS; Prinssen E; Colpaert F; Vacher B; Newman-Tancredi A
    Br J Pharmacol; 2007 May; 151(2):253-65. PubMed ID: 17375086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.